This company listing is no longer active
Hyloris Pharmaceuticals Future Growth
Future criteria checks 6/6
Hyloris Pharmaceuticals is forecast to grow earnings and revenue by 77.4% and 59% per annum respectively. EPS is expected to grow by 55.7% per annum. Return on equity is forecast to be 51.2% in 3 years.
Key information
77.4%
Earnings growth rate
55.7%
EPS growth rate
| Pharmaceuticals earnings growth | 19.4% |
| Revenue growth rate | 59.0% |
| Future return on equity | 51.2% |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 41 | 8 | N/A | 0 | 1 |
| 12/31/2023 | 15 | -8 | N/A | -10 | 2 |
| 12/31/2022 | 10 | -11 | N/A | -10 | 2 |
| 12/31/2021 | 3 | -12 | -12 | -11 | N/A |
| 9/30/2021 | 2 | -12 | -13 | -13 | N/A |
| 6/30/2021 | 1 | -12 | -14 | -14 | N/A |
| 3/31/2021 | 1 | -10 | -7 | -7 | N/A |
| 12/31/2020 | 0 | -7 | -5 | -5 | N/A |
| 9/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 6/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 3/31/2020 | 0 | -6 | -8 | -6 | N/A |
| 12/31/2019 | 0 | -5 | -6 | -5 | N/A |
| 12/31/2018 | 0 | -6 | -5 | -5 | N/A |
| 12/31/2017 | 0 | -4 | -4 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 52U is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.01%).
Earnings vs Market: 52U is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 52U is expected to become profitable in the next 3 years.
Revenue vs Market: 52U's revenue (59% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 52U's revenue (59% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 52U's Return on Equity is forecast to be very high in 3 years time (51.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/02 11:30 |
| End of Day Share Price | 2022/04/04 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hyloris Pharmaceuticals SA is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beatrice Allen | Berenberg |
| Laura Roba | Degroof Petercam |
| David Seynnaeve | Degroof Petercam |